Experienced in Parainfluenza

Dr. Mira Baron

Internal Medicine
2277 Palm Beach Lakes Blvd, 
West Palm Beach, FL 
Experienced in Parainfluenza
2277 Palm Beach Lakes Blvd, 
West Palm Beach, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mira Baron is a primary care provider, practicing in Internal Medicine in West Palm Beach, Florida. Dr. Baron is rated as an Experienced provider by MediFind in the treatment of Parainfluenza. Her top areas of expertise are Migraine with Brainstem Aura, Familial Hemiplegic Migraine, Migraine, and Parainfluenza.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Parainfluenza.

Specialties
Internal Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

2277 Palm Beach Lakes Blvd, West Palm Beach, FL 33409

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Enrollment Status: Completed
Publish Date: March 28, 2024
Intervention Type: Drug
Study Drug: X0002
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.
Enrollment Status: Completed
Publish Date: October 05, 2023
Intervention Type: Combination product
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

2 Total Publications

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Journal: Science (New York, N.Y.)
Published: November 23, 2021
Similar Doctors
Advanced in Parainfluenza
Dr. Ricardo S. Marques
Internal Medicine | General Practice
Advanced in Parainfluenza
Dr. Ricardo S. Marques
Internal Medicine | General Practice

Cora Health Services, Inc.

7015 Beracasa Way, Cora Physical Therapy W Bo, 
Boca Raton, FL 
 (25.0 miles away)
561-939-2033
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Marques is a primary care provider, practicing in Internal Medicine and General Practice in Boca Raton, Florida. Dr. Marques is rated as an Advanced provider by MediFind in the treatment of Parainfluenza. His top areas of expertise are Middle East Respiratory Syndrome (MERS), Familial Combined Hyperlipidemia, Xanthoma, and Cirrhosis. Dr. Marques is currently accepting new patients.

Advanced in Parainfluenza
Dr. David B. Hevert
Internal Medicine
Advanced in Parainfluenza
Dr. David B. Hevert
Internal Medicine

David B Hevert MD PA

3848 Fau Blvd, Suite 210, 
Boca Raton, FL 
 (22.5 miles away)
561-394-3088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Hevert is a primary care provider, practicing in Internal Medicine in Boca Raton, Florida. Dr. Hevert is rated as an Advanced provider by MediFind in the treatment of Parainfluenza. His top areas of expertise are Thrombocytopenia, COVID-19, Myelodysplastic Syndrome (MDS), Gastrostomy, and Endoscopy. Dr. Hevert is currently accepting new patients.

Advanced in Parainfluenza
Dr. David I. Levey
Internal Medicine
Advanced in Parainfluenza
Dr. David I. Levey
Internal Medicine

Medical Specialists Of The Palm Beaches Inc

1905 Clint Moore Rd, Suite 204, 
Boca Raton, FL 
 (20.9 miles away)
561-544-8938
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Levey is a primary care provider, practicing in Internal Medicine in Boca Raton, Florida. Dr. Levey is rated as an Advanced provider by MediFind in the treatment of Parainfluenza. His top areas of expertise are Glossitis, Pernicious Anemia, Vitamin B12 Deficiency, Ureteroscopy, and Pacemaker Implantation. Dr. Levey is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baron's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile